Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | PHASE2 | RECRUITING | 21 | — | — | Feb 20, 2026 | Mar 1, 2027 | May 4, 2026 | 9 | United States |
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | DISC-0974 60 mg (n = 14) administered subcutaneously (SC) every 28 days for 3 doses |
| Placebo | PLACEBO_COMPARATOR | Placebo (n = 7) administered SC every 28 days for 3 doses |
| Name | Type | Description |
|---|---|---|
| DISC-0974 | DRUG | DISC-0974 is administered subcutaneously. |
| Placebo | DRUG | Placebo is administered subcutaneously |
Inclusion Criteria: Participants must meet all the following criteria at screening (unless otherwise specified) to be eligible for enrollment in the study: 1. Aged ≥18 years at the time of signing informed consent. 2. Established diagnosis of IBD (CD, UC, or IBD-unclassified) based on documented f...